Overview

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Status:
RECRUITING

Trial end date:
2026-06-15

Target enrollment:

Participant gender:

Summary

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Phase:

PHASE2

Details

Lead Sponsor:

Derm Texas, PLLC

Collaborator:

Arcutis Biotherapeutics, Inc.

Treatments:

Roflumilast